National Medical Products Administration (NMPA)
Is Amycretin legal in China?
Not approvedNot approved in China; Novo Nordisk has only clinical-trial applications on file.
Not approved as a medicine here.
CDE's public register lists four Novo Nordisk import applications for amycretin (three tablet records accepted in April 2024 and one injection record accepted in December 2024), all at the clinical-trial stage. No marketing application was found and no approval exists, so amycretin cannot lawfully be sold as a medicine in China.
Last verified 2026-09-29 · how we verify
Amycretin elsewhere
Sources (2)
- 01CDE public register of accepted drug applications (受理品种目录浏览)Center for Drug Evaluation (CDE), NMPA · 2026-09-29 · accessed 2026-09-29
- 02Drug Administration Law of the PRC (中华人民共和国药品管理法)National Medical Products Administration (NMPA) · 2019-08-26 · accessed 2026-09-29